GabonTuberculosis profile
Population  2015 1.7 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.1 (0.68–1.7) 65 (39–97)
Mortality (HIV+TB only) 0.054 (<0.01–0.15) 3.2 (0.38–8.8)
Incidence  (includes HIV+TB) 8 (5.9–10) 465 (344–604)
Incidence (HIV+TB only) 0.25 (0.15–0.37) 14 (8.8–21)
Incidence (MDR/RR-TB)** 0.4 (0.23–0.56) 23 (13–32)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.45 (0.16–0.73) 2.7 (1.5–3.9) 3.2 (1.7–4.7)
Males 0.62 (0.39–0.85) 4.2 (3.1–5.4) 4.8 (3.5–6.2)
Total 1.1 (0.73–1.4) 6.9 (5.7–8.2) 8 (5.9–10)
TB case notifications, 2015  
Total cases notified 6 293
Total new and relapse 5 727
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 49%
          - % pulmonary 92%
          - % bacteriologically confirmed among pulmonary 54%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 71% (55–97)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.15 (0.09–0.24)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 795 29%
          - on antiretroviral therapy 588 74%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  280
(170–380)
Estimated % of TB cases with MDR/RR-TB 3.2% (1.4–5) 14% (6.9–21)  
% notified tested for rifampicin resistance 1% 4% 119
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 15, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 4, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 58% 4 843
Previously treated cases, excluding relapse, registered in 2014 50% 479
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013    
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 0%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data